Stock info Chemometec | Filter  Basic-Info

Chemometec

The global pharmaceutical companies gained around 75 percent over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a profitable year for Chemometec investors

The stock gained over the past 12 months at around 53 percent. Over the period 2011-2016 the stock rose a massive 637,5 percent. Chemometec's revenues between 2011 and 2015 were far from constant and moved between 5,28 million euros and 8,21 million euros. Chemometec's net incomes between 2011 and 2015 were very volatile through the time and moved between 0,01 million euros and 1,07 million euros.

Chemometec didn't pay out any dividends (in the past 5 years).

Chemometec' balance mostly consists of equity

As per the end of 2015 the Danish company's balance sheet equaled 8,51 million euros. 2,29 million euros (26,91 percent of the total balance sheet) was financed by debt. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 99. So the stock' value was 99 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Danish stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 579,79 million euros. At the end of 2015 the Danish company had around 15,67 million stocks listed.

All Chemometec's annual reports can be found here. More information about Chemometec can be found it's website. .